PMA device
Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)
Johnson & Johnson Surgical Vision, Inc. · Aid, Surgical, Viscoelastic (LZP, Class III) · First FDA decision Nov 22, 2010, newest Apr 15, 2024Cataract
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
99
Naming "Sodium Hyaluronate Ophthalmic"
MAUDE reports
0
Brand "Sodium Hyaluronate Ophthalmic", since 2015
PubMed studies
24
Mentioning "Sodium Hyaluronate Ophthalmic"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
P810031-S075 · Decided Apr 15, 2024 · 88 days after receipt · Normal 180 Day Track
Device type: AID, SURGICAL, VISCOELASTIC (LZP) · Ophthalmology
P810031-S066 · Decided Nov 25, 2020 · 261 days after receipt · Normal 180 Day Track
Device type: AID, SURGICAL, VISCOELASTIC (LZP) · Ophthalmology
- Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)PMA supplement
P810031-S065 · Decided Apr 29, 2019 · 147 days after receipt · Normal 180 Day Track
Device type: AID, SURGICAL, VISCOELASTIC (LZP) · Ophthalmology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Sodium Hyaluronate Ophthalmic", any status and sponsor, newest update first.
- Recurrent Aphthous Stomatitis Management in Children Using Diode Laser 980 Nanometer Versus Hyaluronic Acid Gel (RCT)Not yet recruiting
National Research Centre, EgyptAcademic, hospital or other
NCT07922681 · 30 participants (planned) · Start Nov 1, 2026 · Primary completion Jan 1, 2027
Device: laser therapy · For: Apthous Ulcer
i+Med S.Coop.Not on our public-company list
NCT07805759 · 49 participants (planned) · Start Jun 8, 2026 · Primary completion Nov 30, 2026
Device: Eye Drops, Lubricant · For: Allergic Conjunctivitis of Both Eyes
Sites: Madrid, Spain
- LacriFill Canalicular Occlusion for Dry Eye After LASIKNot yet recruiting
Mann Eye InstituteAcademic, hospital or other
NCT07911930 · 75 participants (planned) · Start Dec 9, 2026 · Primary completion Dec 31, 2027
Device: LacriFill Canalicular Filler · For: Dry Eye Syndrome
Sites: Houston, Texas
96 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Sodium Hyaluronate Ophthalmic", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LZP
1,607 reports: 550 malfunction, 1,056 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Johnson & Johnson Surgical Vision Inc
Z-0867-2020 · Started Dec 3, 2019 · Posted by FDA Jan 27, 2020
Reason given: Ophthalmic viscosurgical device may be difficult to remove from the eye, leading to increased postoperative intraocular pressure requiring additional intervention. Also, reports of clogging of phacoemulsion equipment tubing, which may lead to delay in the procedure or ocular injury.
Cause as FDA categorized it: Labeling False and Misleading · Device type: Aid, Surgical, Viscoelastic (LZP)
Abbott Medical Optics Inc. (AMO)
Z-2062-2017 · Started Apr 1, 2017
Reason given: Remote possibility that certain solutions in these lots may contain microscopic glass particles due to damage that occurred at the cylinder neck during the manufacturing process.
Cause as FDA categorized it: Process design · Device type: Aid, Surgical, Viscoelastic (LZP)
Abbott Medical Optics Inc. (AMO)
Z-2063-2017 · Started Apr 1, 2017
Reason given: Remote possibility that certain solutions in these lots may contain microscopic glass particles due to damage that occurred at the cylinder neck during the manufacturing process.
Cause as FDA categorized it: Process design · Device type: Aid, Surgical, Viscoelastic (LZP)
5 more recall records with a free account
Published research
The most relevant PubMed records for "Sodium Hyaluronate Ophthalmic"[tiab]. The summary above synthesizes these.
- Effect of sodium hyaluronate ophthalmic solution on peripheral staining of rigid contact lens wearers.
Itoi M, Kim O, Kimura T, et al. · CLAO J · 1995Clinical Trial, Multicenter Study
- Diluting 2.5% Viscoadaptive Sodium Hyaluronate to Prevent Postoperative Intraocular Pressure Rise After Phacoemulsification: A Pilot Study.
Nusef A, Almoosa A, Wagih W · Cureus · 2023
- Diquafosol ophthalmic solution for dry eye treatment.
Nakamura M, Imanaka T, Sakamoto A · Adv Ther · 2012Review
- Topical rebamipide improves lid wiper epitheliopathy.
Itakura H, Kashima T, Itakura M, et al. · Clin Ophthalmol · 2013Case Reports
- Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease.
Baeyens V, Bron A, Baudouin C · J Fr Ophtalmol · 2012Clinical Trial, Phase III, Multicenter Study
- Development of a novel eye drop aid and evaluation of its efficacy.
Kasai Y, Sakamoto M, Matsuda Y, et al. · PLoS One · 2025Research Support, Non-U.S. Gov't
- Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.
Keating GM · Drugs · 2015Comparative Study, Review
- Adhesive retention of sodium hyaluronate ophthalmic viscosurgical devices in an acrylic tube model and in porcine-eye corneal endothelium with different irrigation rates.
Tanaka T, Kimura K, Usui M · J Cataract Refract Surg · 2009Research Support, Non-U.S. Gov't
- Effect of instillation of eyedrops for dry eye on optical quality.
Koh S, Maeda N, Ikeda C, et al. · Invest Ophthalmol Vis Sci · 2013Comparative Study, Research Support, Non-U.S. Gov't
- Clinical Efficacy of 2% Rebamipide in Patients With Video Display Terminal-Associated Dry Eye Disease: A Prospective, Randomized, Double-Blinded Study.
Lee YW, Han SB · Eye Contact Lens · 2024Randomized Controlled Trial
- A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients.
Takamura E, Tsubota K, Watanabe H, et al. · Br J Ophthalmol · 2012Comparative Study, Multicenter Study
- Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena).
Vogel R, Crockett RS, Oden N, et al. · Am J Ophthalmol · 2010Clinical Trial, Phase III, Comparative Study
Other devices of this type
Also filed under product code LZP.
- PROVISC Ophthalmic Viscosurgical DeviceAlcon Research, Ltd. · PMA 2026
- Amvisc & Amvisc Plus OvdBausch & Lomb, Inc. · PMA 2017
- Staarvisc II & Shellgel Sodium HyauronateAnika Therapeutics, Inc. · PMA 2012
- VISCOAT Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2026
- DISCOVISC Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2021
- Cellugel(R) Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2016
- Ocucoat (2% Hydroxpropylmethylcellulose Solution)Bausch & Lomb, Inc. · PMA 2012
- Biolon (1% Sodium Hyaluronate for Ophthalmic Surgery)Altacor , Ltd. · PMA 2005
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.